The remittive effects of alefacept.
The duration of response to treatment with alefacept has been assessed in patients with moderate to severe chronic plaque psoriasis who responded to alefacept therapy in phase 2 and phase 3 clinical studies. In a phase 2 trial, duration of response was based on time to retreatment with alefacept. In two phase 3 studies, the more objective measure of maintenance of a > or =50% reduction from baseline Psoriasis Area and Severity Index (PASI 50) was used. Two patient subsets were analyzed: (1) those who achieved a PASI 75 at any time during the trials and (2) those who achieved a Physician Global Assessment of "clear" or "almost clear" at any time during the trials. Regardless of the criterion used or the route of alefacept administration (intravenous or intramuscular), the median duration of response to alefacept therapy ranged from 7 to 10 months across the three studies. Alefacept is a remittive therapy for psoriasis.
Krueger
Gerald G
GG
Department of Dermatology, University of Utah Health Sciences Center, Salt Lake City, UT 84132, USA. krueger@derm.med.utah.edu
D000077944:Alefacept; D002986:Clinical Trials as Topic; D006801:Humans; D011565:Psoriasis / Q000188:drug therapy*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D012074:Remission Induction
D011993:Recombinant Fusion Proteins; D000077944:Alefacept